DOCSLIB.ORG

15 – Sexually Transmitted Infections: Genital Ulcers Diseases (GUD) Speaker: Khalil Ghanem, MD

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
15 – Sexually Transmitted Infections: Genital Ulcers Diseases (GUD) Speaker: Khalil Ghanem, MD 15 –Sexually Transmitted Infections: Genital Ulcers Diseases (GUD) Speaker: Khalil Ghanem, MD Disclosures of Financial Relationships with Relevant Commercial Interests • None Sexually Transmitted Infections: Genital Ulcers Diseases (GUD) Khalil G. Ghanem, MD, PhD Professor of Medicine Division of Infectious Diseases Johns Hopkins University School of Medicine INCLUDED PHOTOS GENITAL ULCER DISEASES (GUD) • Syphilis (Treponema pallidum) Please note: all photos are freely available • HSV-2 • HSV-1 from the following website unless otherwise • Chancroid (Haemophilus ducreyi) noted: • Lymphogranuloma venereum (LGV) http://www.cdc.gov/std/training/clinicalslide (Chlamydia trachomatis) s/slides-dl.htm • Granuloma inguinale (Donovanosis) (Klebsiella granulomatis) PAIN AND GUD “KEY WORDS” IN GUD Which ulcers are Which ulcers are • SYPHILIS: Single, painless ulcer or PAINFUL? PAINLESS? chancre at the inoculation site with • HSV • Syphilis* heaped-up borders & clean base; painless • Chancroid • LGV (but bilateral LAD (>30% of patients have multiple painful lesions) lymphadenopathy • HSV: multiple, painful, superficial, is PAINFUL) vesicular or ulcerative lesions with • Granuloma *>30% of patients have multiple erythematous base painful lesions inguinale ©2020 Infectious Disease Board Review, LLC 15 –Sexually Transmitted Infections: Genital Ulcers Diseases (GUD) Speaker: Khalil Ghanem, MD “KEY WORDS” IN GUD CONTINUED GUD: CONCEPTS TO KNOW • CHANCROID: painful, indurated, ‘ragged’ genital ulcers & tender suppurative inguinal adenopathy • Organisms that cause disease (50%); kissing lesions on thigh • GI: Painless, progressive (destructive), • Geographic distribution for less “serpiginous” ulcerative lesions, without regional common agents lymphadenopathy; beefy red with white border & highly vascular • Diagnostic approach(es) • LGV: short-lived painless genital ulcer accompanied by painful suppurative inguinal • Therapeutic approach(es) lymphadenopathy; “groove sign” QUESTION #1 QUESTION #1 Which of the following diagnostic tests is A 35-year-old woman presents with a inappropriate to obtain? painless ulcer on her vulva and one on her soft palate following unprotected vaginal A. Serum RPR and receptive oral sex 3 weeks earlier. She B. Serum VDRL has no other symptoms. C. Serum treponemal EIA D. Darkfield microscopy on a specimen obtained Examination reveals the two ulcers with from the oral ulcer heaped-up borders and a clean base. E. Darkfield microscopy on a specimen obtained from the vulvar ulcer EARLY SYPHILIS: CLINICAL SYPHILIS: TAKE-HOME POINTS MANIFESTATIONS • Neurological and ocular manifestations may occur • Incubation ~3 weeks during any stage of syphilis • Primary: chancre; LAD; resolves 3-6 wks • Both treponemal and non-treponemal tests may be • Secondary: Systemic symptoms: low-grade fever, malaise, sore throat, adenopathy nonreactive in primary syphilis but they are almost • RASH: evanescent, copper-colored, macular (dry) rash; followed by a red papular eruption (involving palms and ALWAYS reactive in secondary and early latent soles); mucosal lesions (gray plaques or ulcers) ; syphilis (remember prozone reaction for non- condyloma lata- wart-like lesions that develop in moist areas treponemal test in secondary syphilis) • Other manifestations: uveitis, patchy alopecia, hepatitis (mild elevation of aminotransferases with • Treponemal tests are almost always reactive in late disproportionately high alkaline phosphatase), gastritis, syphilis (once positive always positive) irrespective periostitis, glomerulonephritis ft t thit ©2020 Infectious Disease Board Review, LLC 15 –Sexually Transmitted Infections: Genital Ulcers Diseases (GUD) Speaker: Khalil Ghanem, MD NEUROLOGICAL MANIFESTATIONS OF SYPHILIS • Can occur during any stage of infection • Can be either asymptomatic or symptomatic • Symptomatic Early Neurosyphilis • Occurs within the first year after infection • Mainly among HIV+ persons • Presents as meningitis (headache; photophobia; cranial nerve abnormalities; ocular symptoms) • Symptomatic Late Neurosyphilis (tertiary syphilis) • Usually occurs ~10 years AFTER primary infection • Divided into 2 categories: • Meningovascular • Parenchymatous LATE NEUROSYPHILIS (TERTIARY) OTHER TERTIARY MANIFESTATIONS Meningovascular Parenchymatous Cardiovascular Late benign syphilis • Endarteritis of the small • Due to actual destruction of • 15-30 years after latency • ‘Gummas’ blood vessels of the nerve cells • Men 3X> women • Granulomatous process meninges, brain, and spinal cord. • Tabes Dorsalis: shooting • Aortic aneurysm; aortic involving skin, cartilage, bone (less commonly in • Typical clinical pains, ataxia, cranial nerve insufficiency; coronary manifestations include abnormalities; optic atrophy artery stenosis; viscera, mucosa, eyes, brain) strokes (middle cerebral • General Paresis: dementia, myocarditis artery distribution is • Exceedingly rare in the psychosis, slurring speech; classic) and seizures U.S. Argyll Robertson pupil SYPHILIS: EYES AND EARS SYPHILIS SEROLOGICAL TESTING Eyes Ears Nontreponemal tests Treponemal tests • Ocular manifestation may occur during • Sensorineural hearing loss • RPR (serum) or VDRL (serum or CSF) any stage and may involve any portion w/vestibular complaints • MHA-TP, TPPA, FTA-Abs, EIAs, CIA of the eye • May be used as screening test (sudden or fluctuating • Detect IgG +/- IgM antibodies • Uveitis & neuroretinitis: mainly (traditional algorithm) against treponemal antigens secondary stage hearing loss, ringing or • False+: endemic treponematoses, old • Interstitial keratitis: occurs in both vertigo) age, pregnancy, autoimmune disease • Usually used as confirmatory test congenital (typically at age 5-20; • Congenital (early and late) (APS), viral infections if nontreponemal test reactive 80% bilateral) and acquired (both • Acquired (secondary and late • Reactive result must be confirmed with • Once reactive, always reactive early and late infections) stages) treponemal test • False + may occur with endemic • CSF examination normal in • CSF examination is normal • False negative: PROZONE effect treponemal infections (e.g. yaws, ~30% of cases of ocular in >90% of cases of otic • Four-fold (i.e. 2-dilution) decline after pinta, bejel)or with Lyme disease syphilis syphilis treatment = CURE (irrespective of the end-titer) ©2020 Infectious Disease Board Review, LLC 15 –Sexually Transmitted Infections: Genital Ulcers Diseases (GUD) Speaker: Khalil Ghanem, MD SEROLOGICAL TESTING: SYPHILIS: DIAGNOSTICS DIFFERENT ALGORITHM +EIA/ –RPR / –FTA Abs +EIA/ –RPR / +FTA Abs • Darkfield microscopy for genital ulcers of primary syphilis; sensitivity of serology • False positive EIA • The patient had syphilis in the past and was adequately treated in primary syphilis only~70% • See previous slide • The patient had syphilis in the • Sensitivity of serology for secondary past but was not adequately or early latent syphilis ~100% treated • The patient has early syphilis and • Over time, non-treponemal serological the EIA became positive before titers decline and may become the RPR did (this is rare) nonreactive even in the absence of • Prozone reaction in secondary therapy while treponemal titers remain syphilis reactive for life* SYPHILIS: DIAGNOSTICS CONTINUED SYPHILIS THERAPY • No single test can be used to diagnose • Early stages (primary, secondary, early latent) neurosyphilis • 2.4 MU of long-acting benzathine penicillin or doxycycline • 50% of neurosyphilis cases may have negative CSF 100mg PO BID X 14 days VDRL; it is highly specific, but insensitive • Late latent/unknown duration • CSF treponemal tests are very sensitive but NOT specific • 2.4 MU of long acting benzathine penicillin G IM X3 (over (i.e. high false+) 2 weeks) [7.2 MU total] or doxycycline 100mg po BID X • May be used to rule out neurosyphilis 4 weeks • ~30% of persons with LATE neurosyphilis may have nonreactive SERUM nontreponemal test SYPHILIS THERAPY CONTINUED QUESTION #2 • Neurosyphilis/Ocular syphilis A pregnant HIV+ woman (CD4 260 cells/mm3; HIV RNA <50 copies/ml) on ART presents with a diffuse rash. • Aqueous penicillin 18 to 24 MU IV X 10-14 days • Procaine penicillin 2.4 MU IM qd + probenecid 500 mg po On examination, she has a temperature of 38.3°C and a macular QID X 10-14 days rash on her trunk and extremities including her palms. • Ceftriaxone 1-2g IV/IM X 10-14 days (2nd line regimen) Serum RPR is reactive at a titer of 1:2048 and FTA-ABS is • Jarisch-Herxheimer: within 6 hours (up to 24 reactive hours) after therapy of (usually) early syphilis; She has a history of severe hives to penicillin but has tolerated antipyretics only; may induce early labor cephalosporins. ©2020 Infectious Disease Board Review, LLC 15 –Sexually Transmitted Infections: Genital Ulcers Diseases (GUD) Speaker: Khalil Ghanem, MD QUESTION #2 SYPHILIS & HIV Which of the following antibiotics is most • Clinical manifestations similar but timeline may appropriate? be compressed • HIV+ patients more susceptible to early neurosyphilis A. Azithromycin • Testing and therapy similar to HIV-uninfected B. Benzathine penicillin G • Serological failure is more likely among HIV+ • Serological response may be slower among HIV+ C. Ceftriaxone • Follow-up is more frequent (every 3 months) D. Doxycycline SYPHILIS & PREGNANCY HSV TAKE-HOME MESSAGES • Screen all women at 1st prenatal visit • Both HSV-1 (particularly among young women and MSM)and 2 cause genital infections • Screen all high risk women and those women living in high- • Most people are unaware that they
Load more

Recommended publications
  • Reporting of Diseases and Conditions Regulation, Amendment, M.R. 289/2014
    THE PUBLIC HEALTH ACT LOI SUR LA SANTÉ PUBLIQUE (C.C.S.M. c. P210) (c. P210 de la C.P.L.M.) Reporting of Diseases and Conditions Règlement modifiant le Règlement sur la Regulation, amendment déclaration de maladies et d'affections Regulation 289/2014 Règlement 289/2014 Registered December 23, 2014 Date d'enregistrement : le 23 décembre 2014 Manitoba Regulation 37/2009 amended Modification du R.M. 37/2009 1 The Reporting of Diseases and 1 Le présent règlement modifie le Conditions Regulation , Manitoba Règlement sur la déclaration de maladies et Regulation 37/2009, is amended by this d'affections , R.M. 37/2009. regulation. 2 Schedules A and B are replaced with 2 Les annexes A et B sont remplacées Schedules A and B to this regulation. par les annexes A et B du présent règlement. Coming into force Entrée en vigueur 3 This regulation comes into force on 3 Le présent règlement entre en vigueur January 1, 2015, or on the day it is registered le 1 er janvier 2015 ou à la date de son under The Statutes and Regulations Act , enregistrement en vertu de Loi sur les textes whichever is later. législatifs et réglementaires , si cette date est postérieure. December 19, 2014 Minister of Health/La ministre de la Santé, 19 décembre 2014 Sharon Blady 1 SCHEDULE A (Section 1) 1 The following diseases are diseases requiring contact notification in accordance with the disease-specific protocol. Common name Scientific or technical name of disease or its infectious agent Chancroid Haemophilus ducreyi Chlamydia Chlamydia trachomatis (including Lymphogranuloma venereum (LGV) serovars) Gonorrhea Neisseria gonorrhoeae HIV Human immunodeficiency virus Syphilis Treponema pallidum subspecies pallidum Tuberculosis Mycobacterium tuberculosis Mycobacterium africanum Mycobacterium canetti Mycobacterium caprae Mycobacterium microti Mycobacterium pinnipedii Mycobacterium bovis (excluding M.
    [Show full text]
  • Syphilis Staging and Treatment Syphilis Is a Sexually Transmitted Disease (STD) Caused by the Treponema Pallidum Bacterium
    Increasing Early Syphilis Cases in Illinois – Syphilis Staging and Treatment Syphilis is a sexually transmitted disease (STD) caused by the Treponema pallidum bacterium. Syphilis can be separated into four different stages: primary, secondary, early latent, and late latent. Ocular and neurologic involvement may occur during any stage of syphilis. During the incubation period (time from exposure to clinical onset) there are no signs or symptoms of syphilis, and the individual is not infectious. Incubation can last from 10 to 90 days with an average incubation period of 21 days. During this period, the serologic testing for syphilis will be non-reactive but known contacts to early syphilis (that have been exposed within the past 90 days) should be preventatively treated. Syphilis Stages Primary 710 (CDC DX Code) Patient is most infectious Chancre (sore) must be present. It is usually marked by the appearance of a single sore, but multiple sores are common. Chancre appears at the spot where syphilis entered the body and is usually firm, round, small, and painless. The chancre lasts three to six weeks and will heal without treatment. Without medical attention the infection progresses to the secondary stage. Secondary 720 Patient is infectious This stage typically begins with a skin rash and mucous membrane lesions. The rash may manifest as rough, red, or reddish brown spots on the palms of the hands, soles of the feet, and/or torso and extremities. The rash does usually does not cause itching. Rashes associated with secondary syphilis can appear as the chancre is healing or several weeks after the chancre has healed.
    [Show full text]
  • Disseminated Mycobacterium Tuberculosis with Ulceronecrotic Cutaneous Disease Presenting As Cellulitis Kelly L
    Lehigh Valley Health Network LVHN Scholarly Works Department of Medicine Disseminated Mycobacterium Tuberculosis with Ulceronecrotic Cutaneous Disease Presenting as Cellulitis Kelly L. Reed DO Lehigh Valley Health Network, [email protected] Nektarios I. Lountzis MD Lehigh Valley Health Network, [email protected] Follow this and additional works at: http://scholarlyworks.lvhn.org/medicine Part of the Dermatology Commons, and the Medical Sciences Commons Published In/Presented At Reed, K., Lountzis, N. (2015, April 24). Disseminated Mycobacterium Tuberculosis with Ulceronecrotic Cutaneous Disease Presenting as Cellulitis. Poster presented at: Atlantic Dermatological Conference, Philadelphia, PA. This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact [email protected]. Disseminated Mycobacterium Tuberculosis with Ulceronecrotic Cutaneous Disease Presenting as Cellulitis Kelly L. Reed, DO and Nektarios Lountzis, MD Lehigh Valley Health Network, Allentown, Pennsylvania Case Presentation: Discussion: Patient: 83 year-old Hispanic female Cutaneous tuberculosis (CTB) was first described in the literature in 1826 by Laennec and has since been History of Present Illness: The patient presented to the hospital for chest pain and shortness of breath and was treated for an NSTEMI. She was noted reported to manifest in a variety of clinical presentations. The most common cause is infection with the to have redness and swelling involving the right lower extremity she admitted to having for 5 months, which had not responded to multiple courses of antibiotics. She acid-fast bacillus Mycobacterium tuberculosis via either primary exogenous inoculation (direct implantation resided in Puerto Rico but recently moved to the area to be closer to her children.
    [Show full text]
  • Pdf/Bookshelf NBK368467.Pdf
    BMJ 2019;365:l4159 doi: 10.1136/bmj.l4159 (Published 28 June 2019) Page 1 of 11 Practice BMJ: first published as 10.1136/bmj.l4159 on 28 June 2019. Downloaded from PRACTICE CLINICAL UPDATES Syphilis OPEN ACCESS Patrick O'Byrne associate professor, nurse practitioner 1 2, Paul MacPherson infectious disease specialist 3 1School of Nursing, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada; 2Sexual Health Clinic, Ottawa Public Health, Ottawa, Ontario K1N 5P9; 3Division of Infectious Diseases, Ottawa Hospital General Campus, Ottawa, Ontario What you need to know Box 1: Symptoms of syphilis by stage of infection (see fig 1) • Incidence rates of syphilis have increased substantially around the Primary world, mostly affecting men who have sex with men and people infected • Symptoms appear 10-90 days (mean 21 days) after exposure with HIV http://www.bmj.com/ • Main symptom is a <2 cm chancre: • Have a high index of suspicion for syphilis in any sexually active patient – Progresses from a macule to papule to ulcer over 7 days with genital lesions or rashes – Painless, solitary, indurated, clean base (98% specific, 31% sensitive) • Primary syphilis classically presents as a single, painless, indurated genital ulcer (chancre), but this presentation is only 31% sensitive; – On glans, corona, labia, fourchette, or perineum lesions can be painful, multiple, and extra-genital – A third are extragenital in men who have sex with men and in women • Diagnosis is usually based on serology, using a combination of treponemal and non-treponemal tests. Syphilis remains sensitive to • Localised painless adenopathy benzathine penicillin G Secondary on 24 September 2021 by guest.
    [Show full text]
  • A Rare Case of Tabes Dorsalis
    Journal of Gynecology and Women’s Health ISSN 2474-7602 Case Report J Gynecol Women’s Health Volume 17 Issue 2- November 2019 Copyright © All rights are reserved by Tobe S Momah DOI: 10.19080/JGWH.2019.17.555960 A Rare Case of Tabes Dorsalis Tobe S Momah*, Bhavsar Parth, Jones Shawntiah, Berry Kelsey and Duff David Department of Family Medicine, University of Mississippi Medical Center, USA Submission: November 05, 2019; Published: November 12, 2019 *Corresponding author: Tobe S Momah, Department of Family Medicine, University of Mississippi Medical Center, USA Background Tabes Dorsalis has become a rare clinical presentation in cases of neuro syphilis since the advent of antibiotics. The recent surge in syphilis cases [1], however, has once again raised interest in the diagnosis and treatment of this rare clinical entity. In this case report, a case of tabes dorsalis in an 82 year African American female is presented. She, also, had right peroneal nerve mono neuropathy that challenged the clinical diagnosis of tabes dorsalis and complicated its management. Keywords: Emergency room; Patient’s laboratory; Arterial duplex; Neurology; Magnetic Resonance; Cerebro Spinal; Serology returned; Physical therapy; Tabes dorsalis Abbreviatations: ER: Emergency Room; CT: Computerized Tomography; MRI: Magnetic Resonance Imaging; CSF: Cerebro Spinal Fluid; RPR: Rapid Plasma Reagin; EMG: Electromyography; PT: Physical Therapy Case Report ness of breath, chest pain or loss of consciousness. Patient’s lab- oratory values were significant for low copper (743mcg/l) and thrombocytopeniaPatient was assessed (64,000k/UL). in ER and determined to have impaired sensation in right lower extremity with inability to move the right leg in any direction.
    [Show full text]
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
    [Show full text]
  • WHO GUIDELINES for the Treatment of Treponema Pallidum (Syphilis)
    WHO GUIDELINES FOR THE Treatment of Treponema pallidum (syphilis) WHO GUIDELINES FOR THE Treatment of Treponema pallidum (syphilis) WHO Library Cataloguing-in-Publication Data WHO guidelines for the treatment of Treponema pallidum (syphilis). Contents: Web annex D: Evidence profiles and evidence-to-decision frameworks - Web annex E: Systematic reviews for syphilis guidelines - Web annex F: Summary of conflicts of interest 1.Syphilis – drug therapy. 2.Treponema pallidum. 3.Sexually Transmitted Diseases. 4.Guideline. I.World Health Organization. ISBN 978 92 4 154980 6 (NLM classification: WC 170) © World Health Organization 2016 All rights reserved. Publications of the World Health Organization are available on the WHO website (http://www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (http://www.who.int/about/licensing/ copyright_form/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Genital Herpes and Human Immunodeficiency Virus
    Genital herpes and human immunodeficiency virus: double trouble Connie Celum,1 Ruth Levine,2 Marcia Weaver,3 & Anna Wald1 Abstract The synergistic relationship between herpes simplex virus type 2 (HSV-2) and transmission of human immunodeficiency virus (HIV) can be substantial in developing countries that have high prevalences of both viral infections. Genital herpes, most frequently caused by HSV-2, has become the leading cause of genital ulcer disease worldwide. This review of recent research on genital herpes and enhanced susceptibility to, and transmission of, HIV is part of the “Advances in HIV/AIDS research series” which endeavours to form a bridge between the research into HIV and acquired immunodeficiency syndrome (AIDS) and the practice of HIV/AIDS prevention, care and support in developing countries. Research findings have shown that being seropositive for HSV-2 can increase the risk of HIV acquisition among high-risk HIV-negative people exposed to HIV and, likewise, the infectiousness of individuals co-infected with HIV-1 and HSV-2 can increase during periods of HSV-2 reactivation. These observations have led to the initiation of several intervention trials and could ultimately lead to the setting of new priorities in public health and clinical practice. WHO has recently issued new guidelines for the syndromic management of genital ulcer disease that include antiviral treatment for lesions consistent with genital herpes. The United States Centers for Disease Control and Prevention issued updated Sexually Transmitted Diseases Treatment Guidelines in 2002 that recommended the use of type-specific serological tests for diagnosing HSV-2. Recently launched proof-of-concept, HSV-2 intervention trials in several countries will help to determine the proportion of new HIV infections that could be prevented by suppression of HSV-2, and the findings from these studies will inform those involved in setting prevention and treatment priorities and strategies in developing countries.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,018,158 B2 Onsoyen Et Al
    US0090181.58B2 (12) United States Patent (10) Patent No.: US 9,018,158 B2 Onsoyen et al. (45) Date of Patent: Apr. 28, 2015 (54) ALGINATE OLIGOMERS FOR USE IN 7,208,141 B2 * 4/2007 Montgomery .................. 424/45 OVERCOMING MULTIDRUG RESISTANCE 22:49 R: R388 al al W . aSOC ea. N BACTERA 7,671,102 B2 3/2010 Gaserod et al. 7,674,837 B2 3, 2010 G d et al. (75) Inventors: Edvar Onsoyen, Sandvika (NO); Rolf 7,758,856 B2 T/2010 it. Myrvold, Sandvika (NO); Arne Dessen, 7,776,839 B2 8/2010 Del Buono et al. Sandvika (NO); David Thomas, Cardiff 2006.8 R 38 8. Melist al. (GB); Timothy Rutland Walsh, Cardiff 2003/0022863 A1 1/2003 Stahlang et al. (GB) 2003/0224070 Al 12/2003 Sweazy et al. 2004/OO73964 A1 4/2004 Ellington et al. (73) Assignee: Algipharma AS, Sandvika (NO) 2004/0224922 A1 1 1/2004 King 2010.0068290 A1 3/2010 Ziegler et al. (*) Notice: Subject to any disclaimer, the term of this 2010/0305062 A1* 12/2010 Onsoyen et al. ................ 514/54 patent is extended or adjusted under 35 U.S.C. 154(b) by 184 days. FOREIGN PATENT DOCUMENTS DE 268865 A1 1, 1987 (21) Appl. No.: 13/376,164 EP O324720 A1 T, 1989 EP O 506,326 A2 9, 1992 (22) PCT Filed: Jun. 3, 2010 EP O590746 A1 4f1994 EP 1234584 A1 8, 2002 (86). PCT No.: PCT/GB2O1 O/OO1097 EP 1714660 A1 10, 2006 EP 1745705 A1 1, 2007 S371 (c)(1), FR T576 M 3/1968 (2), (4) Date: Jan.
    [Show full text]
  • Klebsiella Ornithinolytica
    international Journal of Systematic Bacteriology (1 999), 49, 1695-1 700 Printed in Great Britain Phylogenetic evidence for reclassification of Calymmatobacterium granulomatis as Klebsiella granulomatis comb. nov. Jenny 5. Carter,’l2 Francis J. B~wden,~Ivan Ba~tian,~Garry M. Myers,’ K. S. Sriprakash’ and David J. Kemp’ Author for correspondence : David J. Kemp. Tel : + 6 18 8922 84 12. Fax : + 6 18 8927 5 187 e-mail : [email protected] 1 Menzies School of Health By sequencing a total of 2089 bp of the 16s rRNA and phoE genes it was Research, Darwin, demonstratedthat Calymmatobacterium grandomatis (the causative Austra Iia organism of donovanosis) shows a high level of identity with Klebsiella * Centre for Indigenous species pathogenic to humans (Klebsiellapneumoniae, Klebsiella Natural and Cultural Resource Management, rhinoscleromatis). It is proposed that C. grandomatis should be reclassified as Faculty of Aboriginal and Klebsiella granulomatis comb. nov. An emended description of the genus Torres Strait Islander Klebsiella is given. Studies, Northern Territory University, Darwin, Australia 3 Institute of Medical and Keywords : Calymmatobacteriurn, Klebsiella, sequence data, phylogenetic inferences Veterinary Science, Adelaide, Australia 4 AIDS/STD Unit, Royal Darwin Hospital, Darwin, Australia Calymmatobacterium granulomatis is the presumed ganism (Richens, 1991) have prevented further char- causative agent of donovanosis, an important cause of acterization of this relationship. genital ulceration that occurs in small endemic foci in all continents except Europe and Antarctica. The name Non-cultivable pathogenic eubacteria have been C. granulomatis was originally given to the pleo- identified by PCR using primers targeting conserved morphic bacterium cultured from donovanosis lesions genes (Fredricks & Relman, 1996).
    [Show full text]
  • Microbiology & Infectious Diseases
    Case Report Research Article Microbiology & Infectious Diseases Neuro Sarcoidosis Masquerading as Neuroborreliosis Chandra S Pingili1,2,4*, Saleh Obaid3,4,5 Kyle Dettbarn3,4,5, Jacques Tham6 and Greg Heiler7 1Infectious Diseases Department, Eau Claire, Wisconsin, USA. 2Prevea Health, Eau Claire, Wisconsin, USA. 3Eau Claire Medical Group, Eau Claire, Wi, USA. *Correspondence: Chandra Shekar Pingili MD, Infectious Diseases, Sacred Heart 4 Sacred Heart Hospital, Eau Claire, Wisconsin, USA. Hospital, 900 W Claremont Ave Eau Claire, WI 54701, USA, Tel: 917-373-9571; E-mail: [email protected]. 5Pulmonary & Critical Care, Sacred Heart Hospital, Eau Claire, Wisconsin, USA. Received: 13 September 2017; Accepted: 02 October 2017 6Department of Radiology, Sacred Geart Hospital, Eau Claire, Wisconsin, USA. 7Pathologist, Sacred Geart Hospital, Eau Claire, Wisconsin, USA. Citation: Chandra S Pingili, Saleh Obaid, Kyle Dettbarn, et al. Neuro Sarcoidosis masquerading as Neuroborreliosis. Microbiol Infect Dis. 2017; 1(2): 1-8. ABSTRACT Background: Medical syndromes often overlap in clinical presentations. Often there is one or more than underlying etiology responsible for the patient’s Clinical presentation. We are reporting a patient who was initially admitted with fevers and joint pains.Lymes IGG was positive .He was discharged home on Doxycycline and Prednisone suspecting gout. Patient however was re admitted twice within 3 weeks with cognitive impairment. Lymph node biopsy was positive for non Caseating granulomas suggesting Sarcoidosis. Clinically he responded dramatically to steroids. Case Report: 74 year old white male was admitted with fever and multiple joint pains. Tmax was 100.5.WBC was 15 with normal CBC. LFTs were elevated .Rest of the labs were normal.Lymes IGG was positive.
    [Show full text]
  • Ohio Department of Health, Bureau of Infectious Diseases Disease Name Class A, Requires Immediate Phone Call to Local Health
    Ohio Department of Health, Bureau of Infectious Diseases Reporting specifics for select diseases reportable by ELR Class A, requires immediate phone Susceptibilities specimen type Reportable test name (can change if Disease Name other specifics+ call to local health required* specifics~ state/federal case definition or department reporting requirements change) Culture independent diagnostic tests' (CIDT), like BioFire panel or BD MAX, E. histolytica Stain specimen = stool, bile results should be sent as E. histolytica DNA fluid, duodenal fluid, 260373001^DETECTED^SCT with E. histolytica Antigen Amebiasis (Entamoeba histolytica) No No tissue large intestine, disease/organism-specific DNA LOINC E. histolytica Antibody tissue small intestine codes OR a generic CIDT-LOINC code E. histolytica IgM with organism-specific DNA SNOMED E. histolytica IgG codes E. histolytica Total Antibody Ova and Parasite Anthrax Antibody Anthrax Antigen Anthrax EITB Acute Anthrax EITB Convalescent Anthrax Yes No Culture ELISA PCR Stain/microscopy Stain/spore ID Eastern Equine Encephalitis virus Antibody Eastern Equine Encephalitis virus IgG Antibody Eastern Equine Encephalitis virus IgM Arboviral neuroinvasive and non- Eastern Equine Encephalitis virus RNA neuroinvasive disease: Eastern equine California serogroup virus Antibody encephalitis virus disease; LaCrosse Equivocal results are accepted for all California serogroup virus IgG Antibody virus disease (other California arborviral diseases; California serogroup virus IgM Antibody specimen = blood, serum, serogroup
    [Show full text]